Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationNano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degenerationMining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular DegenerationTransfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepComparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration.Biological Modulation of Mouse RPE Cells in Response to Subthreshold Diode Micropulse Laser Treatment.DETECTION OF NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicinesA matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extractionSevere Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysisDevelopment of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.Comment on 'Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab'.Authorship and the role of medical writers.Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.Response to Vallance.Authors' Response to a Letter to the Editor.ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch's Membrane and Causes Its Structural Remodeling.Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light.Models of retinal diseases and their applicability in drug discovery.Early changes in macular optical coherence tomography parameters after Ranibizumab intravitreal injection in patients with exsudative age-related macular degeneration.Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization.[Atrophy of the macula in the context of its wet, age-related degeneration : An inescapable consequence of anti-VEGF therapy?]Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
P2860
Q24193614-B46C2625-2113-4737-8F5B-DF5B28079A7CQ24195003-D141A036-0D9D-4A92-A0C3-CC24DBFBA56BQ30565636-2A826F48-A1FA-4ABE-9B18-9538BB986D8DQ31015035-9F140780-D8E2-4C4C-BFA8-85052EBA6800Q33912465-09FDCCCC-3E77-49BA-BC40-A8589A583B62Q34624487-4BEE5B72-2A45-4B68-B6AA-47767E4DE15EQ34708262-72D5D842-A470-4845-9C08-8C187F4E8B1CQ34740219-11F81E2E-555A-49F9-A7A0-BF59BCF10F97Q35243299-469EF129-E905-4A60-93B1-FF4587404D15Q35585178-F88B4EC6-2086-4ECA-B980-F6D6910BF1F9Q35736348-E806150F-FCAF-42B6-9E45-1FF5E53EBDFCQ36063372-99584062-D9FF-4DBB-8FD8-A586386083A1Q36218094-70151487-8ED3-4BD0-B534-E9B3212D3D65Q36245132-A01C759D-FA57-4AB3-8F5C-7951FDD1E46FQ36374429-1DE6885B-C315-4CCB-9CF0-08FD413F550FQ36738575-8245094F-BCB2-48D6-8830-1976F7D9DC74Q36762577-EA5974C0-F27A-479B-AA5B-0A974571F146Q36788545-135E1626-FF16-438D-AEE3-8D9E79D9DE2FQ36908876-B7ACD6C2-FEA3-4A74-BD9D-63EE962D76BDQ37973348-F2F3A701-2538-4F6B-9512-EA7CBA7091F8Q38003860-6567BE78-12E6-4F1E-B2C3-4307BEF827FCQ38183850-A3E538C2-6398-4014-8F77-4287EB78490FQ38236770-61EEE81A-774A-4213-9CDE-9935B0C37753Q40957787-D01923E3-C40D-4813-8592-A5476552BED9Q43056800-9B571602-0E69-448A-BE61-CFC57EE58198Q43056820-363C36BC-4AC7-4454-9B39-ABCFCC721CB5Q44995662-7B681961-72AA-4DB6-9963-A6253779F422Q46157381-CD72E5FF-1DC9-40E5-A825-4F2B9C2E8F32Q46291590-9DA05768-78B3-42BC-802C-5EFC456AA69BQ47708481-F2CB9050-7A87-4C27-BC5B-A6CB919D62B4Q48180462-D6C305CD-2B5A-4429-A69B-68C90F946497Q49574913-B1F97BEE-C0D9-4986-908A-C39AF3F1B288Q51751149-A21AAF83-53D0-4DEC-8C6B-29A80029F25AQ52609710-1E4D7601-BBF3-467A-952A-06FB8B6AA775Q53018746-E23D2132-F850-472E-97EE-8EDFC6BAD63AQ53373714-986F1B29-0F01-4383-A80C-4C590B6308E1Q54200975-63638648-B73D-4DB6-91F0-4A9D46B7FA4B
P2860
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@ast
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@en
type
label
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@ast
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@en
prefLabel
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@ast
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@en
P2860
P356
P1433
P1476
Preclinical aspects of anti-VE ...... D: ranibizumab and bevacizumab
@en
P2093
P2860
P2888
P304
P356
10.1038/EYE.2011.66
P50
P577
2011-04-01T00:00:00Z